Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute

Depomed

Status and phase

Completed

Phase 4

Conditions

Pain

Treatments

Drug: Zipsor®

Study type

Interventional

Funder types

Industry

Identifiers

NCT01982539

81-0072

Details and patient eligibility

About

As part of the PREA(Pediatric Research Equity Act) commitment, the objective of the study is to confirm safety and tolerability of 25 mg of Zipsor® in clinical pediatric subjects.

Full description

Open-label study, subjects will be dosed with Zipsor® for the treatment of mild to moderate acute pain for up to 4 days.

Enrollment

25 patients

Sex

All

Ages

12 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male and female subjects between 12-17 years of age.
Subjects must be post-op, having mild or moderate acute pain.

Other inclusions apply.

Exclusion criteria

Subject has a known history of allergic reaction, hypersensitivity to diclofenac, aspirin, acetaminophen, or reaction to the non-active ingredients of the study medication.
Subject has been taking analgesic for 48-72 hours prior to Screening.
Subject has a history of any GI event greater than 6 months before Screening.
Subject is currently receiving any medication that is contraindicated for use concomitantly with diclofenac or acetaminophen.
Subject has previously participated in another clinical study of Zipsor or taking Zipsor for any other indication.
Subject is requiring treatment for pre-existing hypertension.

Other exclusions apply.